153 results about "Dipyridamole" patented technology

Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers.

The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use.

Agonists of the adenosine A2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclo-propyladenosine, 5'N-methylcarboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

The invention discloses a dipyridamole self-emulsifying medicament administration system, which is characterized by comprising the following components in percentage by mass: dipyridamole 0.5-10, an oil phase 20-80, a surfactant 10-70 and an auxiliary surfactant 0-50. The system has the advantages that: self-emulsifying capsules prepared by using the dipyridamole, the oil phase, the surfactant and the auxiliary surfactant change into emulsion by slightly stirring after disintegrating in water or spontaneously change into emulsion in vivo under the action of the peristalsis of the gastrointestinal tracts after being delivered by oral taking, wherein the particle size of the emulsion is 10 to 500 nanometers; the dissolution of the dipyridamole is improved greatly; after the system is taken orally, the absorption of the medicament is improved greatly, the bioavailability is improved and the individual difference is reduced; and the preparation process is simple and is suitable for large-scale production of medical enterprises.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a medicament microsphere and a preparation method thereof. The medicament microsphere comprises medicinal materials, a high polymer material and a surfactant, wherein the ratio of the medicament to the high polymer material is 1:(1-3); the medicament preferably is celecoxib, ketoprofen, dipyridamole and nimodipine. The medicament microsphere is prepared by adopting an O/W emulsified solvent diffusion-volatilization method. The O/W emulsified solvent diffusion-volatilization method comprises the following steps: respectively weighing the medicinal materials, the high polymer material and a release regulator according to the prescription amount, and then adding the weighted materials to an organic solvent; ultrasonically or mechanically stirring and dissolving as a disperse phase; taking a surfactant solution as a continuous phase; warming and stirring after low-temperature emulsification under an agitation state, so as to remove an organic solvent; and then carrying out solid separation, washing by distilled water, and drying, so as to obtain the medicament microsphere. Thus, the prepared microsphere is high in encapsulation efficiency and high in yield.

The invention relates to a method of treating and preventing thromboembolic disorders, comprising administering dipyridamole in combination with an antithrombotic selected from direct thrombin inhibitors, factor Xa inhibitors and combined thrombin/factor Xa inhibitors to a patient, pharmaceutical compositions suitable for this method of treatment as well as the use of dipyridamole for the manufacture of these pharmaceutical compositions.

The invention discloses a reagent for stabilization of blood sample cells. The reagent comprises 100 micromoles per liter of L beta-cyclodextrin, 100 micromoles per liter of disodium cromoglycate, 0.05% of potassium dichromate, 50 micromoles per liter of triflusal, 100 micromoles per liter of Terutroban, 11 millimoles per liter of sodium citrate, 1.5 millimoles per liter of theophylline, 20 micromoles per liter of dipyridamole, 0.37 millimoles per liter of adenosine, 20 millimoles per liter of glucose and 1.25 millimoles per liter of LPEG. The reagent can stabilize blood cells for at least 36h and prevent blood cell aggregation. Through the reagent, a blood sample subjected to treatment does not influence follow-up sample molecule analysis. The reagent can be widely used for blood sample molecule analysis and detection and is especially suitable for cell or molecular detection such as a microfluidic technology with strict sample cell requirements and an analysis technology platforms such as a flow cytometer with strict sample cell requirements.

Platelet activation is measured by determining Mean Platelet Component (MPC) of suspended blood platelets, using a specific anticoagulant composition. The composition comprises at least one component for effecting platelet sphering (for example EDTA), and at least one platelet antagonist (for example at least one of, and preferably all three of theophylline, adenosine and dipyridamole).

A slowly-releasing compound medicine in the form of tablet for treating and preventing thrombosis and apoplexy is prepared from aspirin, 2-(acetoxy) benzoic acid, slow-releasing dipyridamole, 2,2',2'',2''', [(4,8-dipiperidylpyrimido[5,4-d] pyrimidine-2,6-diyl) dihyponitido]-tetraethanol through granulating, tabletting and coating. Its advantages are high curative effect and equickly taking its effect.

The invention provides a preparation method of ginkgo dipyridolum injection with high content of ginkgo terpene lactones. The preparation method comprises the following steps: 1), collecting, processing, detecting and classifying ginkgo leaves; 2), extracting and preparing ginkgo terpene lactones extract from ginkgo leaves; 3), extracting ginkgo leaf flavonoid extract; 4), reflowing ginkgo leaf flavonoid extract and partial dipyridamole by adding water, and then filtering so as to be prepared into mixed liquor; 5), mixing the mixed liquor, ginkgo terpene lactones extract, the rest dipyridamole and auxiliary material to be prepared into ginkgo dipyridolum injection as per conventional preparation method; and in the ginkgo dipyridolum injection, the content of the total ginkgo leaf flavonoid and that of the dipyridamole conform to the conventional requirements, and the content of the ginkgo terpene lactones ranges from 0.5 to 1.2 mg/mL.

The present invention discloses one kind of soft diphyidamole capsule and its preparation process. The medicine consists of medicine liquid and capsule shell, the medicine liquid contains diphyidamole, matrix and stabilizer, and the capsule shell contains gelatin, glycerin, water, preservative and light screening agent. Compared with available diphyidamole preparations, the present invention is even suitable for children and other people incapable of taking care of himself to take and has the advantages of high bioavailability, high stability, accurate content, etc.

The invention provides a method for preparing ginkgodipyidamolum injection. The method comprises the following steps of: 1) extracting a ginkgo leaf extract from ginkgo leaves; 2) extracting the ginkgo leaf extract once again with over 90 percent ethanol so as to refine the ginkgo leaf extract; 3) adding water into the refined ginkgo leaf extract and dipyridamole for inverse flow and filtering so as to obtain ginkgo leaf extracting solution; and 4) mixing the ginkgo leaf extracting solution, the dipyridamole and auxiliary materials so as to obtain the ginkgodipyidamolum injection, wherein in the ginkgodipyidamolum injection, the weight ratio of the ginkgo leaf extracting solution to the dipyridamole based on total ginkgo flavone-glycoides is 0.9-1.1:0.3-0.5. The method of the invention has the advantages of effectively removing various impurities, enhancing medicament effectiveness, improving the quality stability of the ginkgodipyidamolum injection and reducing safety risk.

The present invention is directed to pharmaceutical capsules comprising extended release formulations of dipyridamole, processes for preparing such dipyridamole extended release formulations and their use in the treatment of stroke.

The invention provides a method for preparing aspirin and dipyridamole multilayer tablets, which is characterized by comprising: preparing dipyridamole sustained-release tablet cores by tabletting; and coating a stomach soluble insulation layer, an aspirin quick-release layer and a stomach soluble protective layer in turn. The method has the advantage that aspirin common release and dipyridamole sustained-release compound preparations are prepared by using conventional pharmaceutical equipment.

A gingko-dipyridamole injection for treating cerebral thrombus, cerebrovascular spasm, cerebral insufficiency, ischemic heart disease, ischemic retinosis, etc is prepared from gingko leaves through breaking, reflux extracting in alcohol, concentrating, filtering, resin adsorption, alcohol eluting to obtain liquid extract, mixing with dipyridamole in dark condition, filling N2, pouring in containers, sterilizing, lamp examining, and packing.

The present invention provides pharmaceutical formulations of dipyridamole and acetylsalicylic acid, methods of making thereof, and methods of using thereof.

The invention relates to dipyradimole orally disintegrating tablet and a preparation method thereof, which pertains to a pharmaceutic preparation field. Components and mass percentages thereof of the orally disintegrating tablet are: 5-50 percent of dipyradimole, 20-70 percent of stuffing agent, 10-40 percent of disintegrating agent, 1-5 percent of effervescent, 0-3 percent of correctant, 0.5-1.8 percent of lubricant and 8-20 percent of adhesive. The method of the invention comprises the following steps: 1) the stuffing agent, the disintegrating agent, the correctant and the effervescent are respectively ground for 30-60min and then fully blended into a mixture; 2) the dipyradimole is ground and added in the mixture cumulatively; after fully blended, the mixture passes through a 100 mesh sieve for 2-3 times; 3) the mixture is made into soft material by the adhesive; then the soft material is pelletized through a 16 mesh sieve and forced-air dried for 4-6 hours at the temperature ranging from 40-50 DEG C; the pelletized granules are sifted by a 20 mesh sieve; the lubricant is added in the pelletized granules and fully blended to prepare the dipyradimole orally disintegrating tablet after stamping and slice production. The orally disintegrating tablet of the invention has the advantages of short disintegrating time, rapid effect and convenient using, etc.

The invention discloses an antitumor drug with double active components, and an application thereof. The antitumor drug comprises an independent first active component and an independent second active component. The independent first active component comprises at least two of A, B and C. The A comprises Dipyridamole and pharmaceutically acceptable derivatives of Dipyridamole or pharmaceutically acceptable analogues of Dipyridamole or pharmaceutically acceptable salts of Dipyridamole. The B comprises Ubenimex bestatin and pharmaceutically acceptable derivatives of Ubenimex bestatin or pharmaceutically acceptable analogues of Ubenimex bestatin or pharmaceutically acceptable salts of Ubenimex bestatin. The C comprises Dexamethasone and pharmaceutically acceptable derivatives of Dexamethasone or pharmaceutically acceptable analogues of Dexamethasone. The independent second active component comprises Taxol, ADM, DDP, MMC, 5-FM, Gemcitabine or a tyrosine kinase inhibitor. The antitumor drug provided by the invention can effect on multiple targets and multiple paths, and thus antineoplastic effects of the antitumor drug are clear and obvious.

A method of treatment of the human or non-human animal body for treating or preventing MMP-9-dependent disorders is disclosed, for example vascular syndromes, damages or diseases, atherosclerotic damages, arthritic conditions, inflammatory reactions, autoimmune reactions or proliferative diseases, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing dipyridamole, mopidamole or a pharmaceutically acceptable salt thereof, and the use of dipyridamole or mopidamole for the manufacture of a corresponding pharmaceutical composition.

The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.

The invention provides methods and compositions for treating or inhibiting the development of osteoarthritis in a subject having osteoarthritis or at risk for developing osteoarthritis and for stimulating or increasing cartilage production or formation in a subject. The methods feature administering to the subject a therapeutically effective amount of a composition comprising one or more agent from among adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. The adenosine receptor may be an A₁, A_2A, A_2B and A₃ adenosine receptor. The agent that upregulates or increases the amount of or the biological activity of adenosine may be dipyridamole or ticagrelor. The composition may be administered via intraarticular injection such as injection into the synovial fluid of a joint. The composition may be effective to reduce or inhibit degeneration or damage to cartilage or to stimulate or increase cartilage production or formation. The composition may be a liposomal composition or contain a liposome.